Twin Tree Management LP Has $2.97 Million Position in Illumina, Inc. (ILMN)
Twin Tree Management LP lifted its position in Illumina, Inc. (NASDAQ:ILMN) by 1,325.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,107 shares of the life sciences company’s stock after purchasing an additional 15,907 shares during the period. Twin Tree Management LP’s holdings in Illumina were worth $2,968,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently bought and sold shares of ILMN. Nisa Investment Advisors LLC increased its holdings in Illumina by 41.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock worth $1,056,000 after acquiring an additional 1,800 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in Illumina in the 1st quarter worth $212,000. Russell Investments Group Ltd. increased its holdings in Illumina by 83.4% in the 1st quarter. Russell Investments Group Ltd. now owns 125,997 shares of the life sciences company’s stock worth $21,502,000 after acquiring an additional 57,290 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in Illumina by 80,307.7% in the 1st quarter. Canada Pension Plan Investment Board now owns 20,906 shares of the life sciences company’s stock worth $3,567,000 after acquiring an additional 20,880 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new stake in Illumina in the 1st quarter worth $117,000. Hedge funds and other institutional investors own 93.34% of the company’s stock.
Illumina, Inc. (NASDAQ ILMN) traded up 0.81% on Thursday, reaching $209.09. 184,566 shares of the company’s stock were exchanged. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $209.42. The company has a 50 day moving average price of $190.34 and a 200-day moving average price of $178.19. The company has a market capitalization of $30.53 billion, a PE ratio of 41.95 and a beta of 0.81.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. During the same period last year, the business posted $0.86 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current year.
In other Illumina news, SVP Charles Dadswell sold 145 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $174.24, for a total transaction of $25,264.80. Following the completion of the sale, the senior vice president now directly owns 10,646 shares in the company, valued at approximately $1,854,959.04. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $195.00, for a total value of $1,950,000.00. Following the sale, the senior vice president now owns 76,585 shares of the company’s stock, valued at $14,934,075. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 145,560 shares of company stock valued at $26,902,430. Company insiders own 1.60% of the company’s stock.
ILMN has been the subject of several recent analyst reports. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target for the company. in a report on Wednesday, June 21st. Barclays PLC reissued a “hold” rating and issued a $150.00 price target on shares of Illumina in a report on Wednesday, July 19th. BidaskClub lowered shares of Illumina from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 price target for the company in a report on Thursday, July 27th. Finally, Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and boosted their price target for the stock from $170.00 to $215.00 in a report on Monday, August 7th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company’s stock. Illumina currently has an average rating of “Hold” and an average price target of $177.01.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.